China’s Ascentage Pharma targets $1.8b valuation in US IPO 2025-01-22T05:06:22-05:00January 22nd, 2025| share this article![#item_full_content] Read More share this article! Related Posts Forensic audit reveals Temasek-backed eFishery’s revenue was inflated nearly 5x January 22nd, 2025 China’s Zijin Mining vies with Glencore after record year for profits January 22nd, 2025 Trump’s America First Trade Policy: US-China 2020 deal is again under scrutiny January 22nd, 2025 BYD’s labour woes in Brazil, US bans Chinese tech in smart cars: 7 EV reads January 22nd, 2025
